Esperion Therapeutics Inc

ESPR

Company Profile

  • Business description

    Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

  • Contact

    3891 Ranchero Drive
    Suite 150
    Ann ArborMI48108
    USA

    T: +1 734 887-3903

    E: [email protected]

    https://www.esperion.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2026

    Employees

    304

Stocks News & Analysis

stocks

Goldman Sachs Earnings: Valuations remain stretched

We raise our fair value estimate for Goldman Sachs stock.
stocks

Major ASX listed miners overvalued

We’ve adjusted our fair values after updating our commodity price assumptions.
stocks

Undervalued ASX share with pathway to positive cash flow

Higher sales and a new loan facility increase our conviction.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,194.9012.40-0.13%
CAC 408,112.02146.92-1.78%
DAX 4024,959.06338.07-1.34%
Dow JONES (US)49,359.3383.11-0.17%
FTSE 10010,195.3539.94-0.39%
HKSE26,563.90281.06-1.05%
NASDAQ23,515.3914.63-0.06%
Nikkei 22553,583.57352.60-0.65%
NZX 50 Index13,580.29137.81-1.00%
S&P 5006,940.014.46-0.06%
S&P/ASX 2008,874.509.20-0.10%
SSE Composite Index4,114.0012.090.29%

Market Movers